Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05768490

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

A Prospective, Multicenter, Randomized, Controlled Clinical Study of Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Sponsor: Sun Yat-sen University

Conditions Brain Metastases EGFR Activating Mutation Radiotherapy

Interventions Almonertinib brain radiotherapy

Updated 3 times since 2023 Last updated: Mar 13, 2023 Started: Mar 15, 2023 Primary completion: Dec 31, 2028 Completion: Dec 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Brain Metastases and EGFR Activating Mutation and is currently actively recruiting participants. Sun Yat-sen University leads this study, which shows 3 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Apr 2023 — Jul 2024 [monthly]

Recruiting PHASE3

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangdong, China